Your browser doesn't support javascript.
loading
Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos, Petros; Bozorgmehr, Farastuk; Brückner, Lena; Chung, Inn; Krisam, Johannes; Schneider, Marc A; Stenzinger, Albrecht; Eickhoff, Regina; Mueller, Daniel W; Thomas, Michael.
Affiliation
  • Christopoulos P; Department of Thoracic Oncology, Thoraxklinik at University Hospital of Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany.
  • Bozorgmehr F; Translational Lung Research Center Heidelberg TLRCH, Member of the German Center for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany.
  • Brückner L; Department of Thoracic Oncology, Thoraxklinik at University Hospital of Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany.
  • Chung I; Translational Lung Research Center Heidelberg TLRCH, Member of the German Center for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany.
  • Krisam J; Department of Thoracic Oncology, Thoraxklinik at University Hospital of Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany.
  • Schneider MA; Translational Lung Research Center Heidelberg TLRCH, Member of the German Center for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany.
  • Stenzinger A; Department of Thoracic Oncology, Thoraxklinik at University Hospital of Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany.
  • Eickhoff R; Translational Lung Research Center Heidelberg TLRCH, Member of the German Center for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany.
  • Mueller DW; University Hospital of Heidelberg, Institute of Medical Biometry and Informatics, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.
  • Thomas M; Translational Lung Research Center Heidelberg TLRCH, Member of the German Center for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany.
BMC Cancer ; 21(1): 743, 2021 Jun 28.
Article in En | MEDLINE | ID: mdl-34182952
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organophosphorus Compounds / Pyrimidines / Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / Anaplastic Lymphoma Kinase / Lung Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Germany Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organophosphorus Compounds / Pyrimidines / Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / Anaplastic Lymphoma Kinase / Lung Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Germany Country of publication: United kingdom